子宫内膜异位症患者血清孕酮浓度与冻胚移植周期皮下补充孕酮的关系
这项回顾性队列纳入2019年1月至2022年12月某大学附属生殖中心的985个人工周期冻胚移植周期,均使用阴道孕酮600 mg/天,其中子宫内膜异位症组168个周期、对照组817个周期。移植前孕酮低于10.6 ng/ml时给予皮下孕酮25 mg/天补充。结果显示两组移植前孕酮低于10.6 ng/ml的可能性相似(aOR 0.98,95% CI 0.65-1.47),活产率在调整后亦相当;妊娠试验日孕酮高于第90百分位(23.31 ng/ml)与更高的临床妊娠率和活产率相关。
要点
- 子宫内膜异位症与对照组移植前孕酮低于10.6 ng/ml的可能性相似(aOR 0.98,95% CI 0.65-1.47)。
- 以孕酮低于10.6 ng/ml的子宫内膜异位症组为参照,各组活产率调整后相当。
- 妊娠试验日孕酮高于23.31 ng/ml与更高的临床妊娠率和活产率相关。
核心结论
- 子宫内膜异位症周期与对照周期移植前孕酮浓度相当,阴道孕酮联合皮下补充后活产率不受子宫内膜异位症状态影响。
研究设计与样本
- 回顾性队列研究,纳入2019年1月至2022年12月某大学附属生殖中心的985个人工周期冻胚移植周期,均使用阴道孕酮600 mg/天。
- 其中子宫内膜异位症组168个周期(17.05%,来自128例患者),对照组817个周期(来自649例患者)。
- 移植前孕酮低于10.6 ng/ml时给予皮下孕酮25 mg/天补充。
- 按孕酮阈值和子宫内膜异位症状态分为四组:组1为子宫内膜异位症且孕酮低于10.6 ng/ml并补充(参照组,51个周期);组2为子宫内膜异位症且孕酮不低于10.6 ng/ml(117个周期);组3为对照且孕酮低于10.6 ng/ml并补充(274个周期);组4为对照且孕酮不低于10.6 ng/ml(543个周期)。
主要发现
- 移植前孕酮低于10.6 ng/ml的可能性在子宫内膜异位症组与对照组之间相似(aOR 0.98,95% CI 0.65-1.47)。
- 调整年龄、BMI和胚胎质量后,组1与组2(aOR 0.79,95% CI 0.36-1.74)、组3(aOR 0.91,95% CI 0.45-1.84)和组4(aOR 1.39,95% CI 0.71-2.74)的活产率相当。
- 妊娠试验日孕酮高于第90百分位(23.31 ng/ml)与更高的临床妊娠率相关:对照组为73% vs 50.5%(P <0.001),子宫内膜异位症组为83.3% vs 46.1%(P = 0.016)。
- 妊娠试验日孕酮高于第90百分位(23.31 ng/ml)与更高的活产率相关:对照组为63.5% vs 38.2%(P <0.001),子宫内膜异位症组为66.7% vs 32.8%(P = 0.027)。
关键数值与推荐
- 移植前孕酮低于10.6 ng/ml时给予皮下孕酮25 mg/天补充。
- 妊娠试验日孕酮第90百分位为23.31 ng/ml。
临床怎么用
- 子宫内膜异位症患者人工周期冻胚移植前孕酮低于10.6 ng/ml时,按本研究方案给予皮下孕酮25 mg/天补充后活产率与对照组相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Are there differences between patients with and without endometriosis in progesterone concentrations the day before artificial-cycle frozen embryo transfer (AC-FET) and in live birth rate (LBR) following subcutaneous progesterone when indicated? DESIGN: This retrospective cohort included 985 AC-FET cycles with vaginal progesterone (600 mg/day) from January 2019 to December 2022 at a university-affiliated fertility centre. Among them, 168 cycles (17.05%) were from patients with endometriosis (n = 128) and 817 from controls (n = 649). LBR was evaluated based on progesterone the day before transfer. Subcutaneous progesterone (25 mg/day) was given when <10.6 ng/ml. Cycles were divided into four groups: 1 (endometriosis, reference, 51 cycles) and 3 (controls, 274 cycles) with progesterone <10.6 ng/ml plus supplementation; 2 (endometriosis, 117 cycles) and 4 (controls, 543 cycles) with progesterone ≥10.6 ng/ml. RESULTS: The likelihood of progesterone <10.6 ng/ml before transfer was similar between groups (adjusted odds ratio [aOR] 0.98, 95% CI 0.65-1.47). After adjustment for age, BMI and embryo quality, LBR were comparable between group 1 and groups 2 (aOR 0.79, 95% CI 0.36-1.74), 3 (aOR 0.91, 95% CI 0.45-1.84) and 4 (aOR 1.39, 95% CI 0.71-2.74). Higher progesterone >90th percentile (23.31 ng/ml) on pregnancy test day was associated with higher clinical pregnancy (controls: 73% vs 50.5%, P <0.001; endometriosis: 83.3% vs 46.1%, P = 0.016) and LBR (controls: 63.5% vs 38.2%, P <0.001; endometriosis: 66.7% vs 32.8%, P = 0.027). CONCLUSIONS: Progesterone concentrations before transfer are comparable between endometriosis and control cycles. Vaginal progesterone with subcutaneous supplementation leads to comparable LBR, regardless of endometriosis status.
引用
- Sachs-Guedj N, Coroleu B, Álvarez M, et al. Serum progesterone concentrations and subcutaneous progesterone supplementation in endometriosis: artificial-cycle frozen embryo transfer. Reprod Biomed Online. 2025. PMID: 41108829. doi:10.1016/j.rbmo.2025.105107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。